Tratamiento con clorhidrato de epinastina al 0.05 en pacientes con síndrome de disfunción lagrimal moderado / Treatment with epinastine hydrochloride to 0.05 in patients with moderate tear dysfunction syndrome

Antihistamínicos como el clorhidrato de epinastina tienen actividad antinflamatoria y podrían usarse como tratamiento del síndrome de ojo seco. Objetivo: evaluar los cambios en la sintomatología, película lagrimal y superficie ocular antes y después del tratamiento con clorhidrato de epinastina en pacientes con síndrome de ojo seco. Materiales y métodos: se realizó un estudio piloto doble ciego en 20 pacientes con diagnóstico clínico de ojo seco moderado. Un ojo de cada paciente recibió tratamiento con clorhidrato de epinastina al 0,05 % y el otro recibió hialuronato de sodio al 0,4 %. Los dos ojos recibieron suplemento lagrimal con hialuronato de sodio al 0,4 %. La dosis de tratamiento fue una gota tres veces al día por 45 días. Antes del tratamiento y 30 y 45 días después, se aplicó cuestionario validado para ojo seco (osdi), test de Schirmer 1, but y lisamina verde. Se aplicó la prueba t de Student y rangos de Wilcoxon. Resultados: se encontró un mejoría estadísticamente significativa en sintomatología a l s 30 días de intervención con epinastina (p = 0,000) y 45 días (p = 0,0000). En la superficie ocular hubo mejoría clínica y significativa estadísticamente a los 45 días (p = 0,0001). No se encontraron cambios significativos en la calidad ni en la cantidad de la película lagrimal. La reducción en la sintomatología y el grado de tinción con la epinastina a los 45 días fue estadísticamente significativa (p < 0,05) con respecto al grupo control. Conclusión: la combinación clorhidrato de epinastina al 0,05% y hialuronato de sodio al 0,4% mejora la sintomatología y la superficie ocular en los pacientes con ojo seco moderado. Tratamiento con clorhidrato de epinastina al 0,05 % en pacientes con síndrome de disfunción lagrimal moderado.

Treatment with Epinastine Hydrochloride to 0.05% in Patients with Moderate Tear Dysfunction Syndrome Antihistamines such as epinastine hydrochloride have anti-inflammatory activity and could be used as a treatment for dry eye syndrome. Objective: To assess changes in symptoms, tear film and ocular surface before and after treatment with epinastine hydrochloride in patients with dry eye syndrome. Materials and methods: A double-blind pilot study was carried out in 20 patients with clinical diagnosis of moderate dry eye. One eye of each patient was treated with 0.05% of epinastine hydrochloride and the other received 0.4% of sodium hyaluronate. Both eyes received tear supplement with 0.4% of sodium hyaluronate. The treatment dose was one drop three times a day for 45 days. Before treatment and 30 and 45 days after, the validated questionnaire for dry eye (osdi), the Schirmer 1 Test, but and lissamine green were used. The Student’s t test and Wilcoxon ranges were used. Results: A statistically significant improvement in symptoms after 30 days of the intervention with epinastine was found (p = 0.000) and after 45 days (p = 0.0000).In the ocular surface there was clinically and statistically significant improvement after 45 days (p = 0.0001). No significant changes were found in quality or quantity of the tear film. The reduction in symptoms and in the degree of staining with epinastine after 45 days was statistically significant (p < 0.05) compared with the control group. Conclusion: The combination of epinastine hydrochloride 0.05% and sodium hyaluronate 0.4% improves symptoms and the ocular surface in patients with moderate dry eye.

Intraocular pressure and tear secretion in Saanen goats with different ages / Pressão intraocular e produção lacrimal em cabras da raça Saanen com diferentes idades

This study aimed to compare the normal intraocular pressure (IOP) and tear secretion, by means of applanation tonometry and the Schirmer tear test-1 (STT-1), in goats of the Saanen breed with different ages, and at different time points. Thirty six goats, free of ocular abnormalities, were grouped into three different age categories (n=12), animals with 45, 180 and 549 days of age. STT-1 and IOP measurements were carried out always at 9:00am and 7:00pm, during three consecutive days. Results were evaluated statistically (P<0.05). Regarding the time of the day, overall IOP values were significantly lower at 7:00 pm (P<0.001) in individuals with 45 days of age; whereas STT-1 values were significantly higher at 7:00pm (P=0.004) in goats with 549 days of age. Considering the sum of three days, both parameters were significantly lower in individuals with 45 days of age (P<0.001). Intraocular pressure and tear secretion values increase until 180 days of age in the Saanen breed of goats.

Objetivou-se comparar os valores normais de pressão intraocular (PIO) e de produção lacrimal, através de tonometria de aplanação e do teste da lágrima de Schirmer-1 (TLS-1) em cabras da raça Saanen, com diferentes idades e momentos. Trinta e seis cabras da raça Saanen, livres de afecções oculares, foram agrupadas em três categorias etárias (n=12), compreendendo animais com 45, 180 e 549 dias de idade. O TLS-1 e a PIO foram aferidos sempre às 9:00 e às 19:00, durante três dias consecutivos. Os resultados foram avaliados estatisticamente (p<0,05). Relativamente ao horário do dia, a PIO foi significativamente menor às 19:00 (p<0,001) nos animais com 45 dias de idade; os valores do TLS-1 foram significativamente maiores às 19:00 (p=0,004) nas cabras com 549 dias de idade. Considerando-se a somatória dos três dias, ambos os parâmetros foram significativamente menores nos indivíduos com 45 dias de idade (p<0,001). A pressão intraocular e a produção lacrimal em cabras da raça Saanen se elevam de forma significativa até os 180 dias de idade.